Tanja Rothgangl

Tanja Rothgangl

Auto-generated profile, based on publicly available information

Tanja Rothgangl

Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2021 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
TRTanja Rothgangl
Tanja Rothgangl
MDMelissa K. Dennis
Melissa K. Dennis
PLPaulo J. C. Lin
Paulo J. C. Lin
RORurika Oka
Rurika Oka
DWDominik Witzigmann
Dominik Witzigmann
GSGerald Schwank
Gerald Schwank
Most known pathogenic point mutations in humans are C•G to T•A substitutions, which can be directly repaired by adenine base editors (ABEs). In this study, we investigated the efficacy and safety of ABEs in the livers of mice and cynomolgus macaques for the reduction of blood low-density lipoprotein (LDL) levels. Lipid nanoparticle–based delivery of mRNA encoding an ABE and a single-guide RNA targetingPCSK9, a negative regulator of LDL, induced up to 67% editing (on average, 61%) in mice and up to 34% editing (on average, 26%) in macaques. Plasma PCSK9 and LDL levels were stably reduced by 95% and 58% in mice and by 32% and 14% in macaques, respectively. ABE mRNA was cleared rapidly, and no off-target mutations in genomic DNA were found. Re-dosing in macaques did not increase editing, possibly owing to the detected humoral immune response to ABE upon treatment. These findings support further investigation of ABEs to treat patients with monogenic liver diseases.

16 March 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
DBDesirée Böck
Desirée Böck
TRTanja Rothgangl
Tanja Rothgangl
LVLukas Villiger
Lukas Villiger
LSLukas Schmidheini
Lukas Schmidheini
MMMai Matsushita
Mai Matsushita
GSGerald Schwank
Gerald Schwank
Prime editing is a highly versatile CRISPR-based genome editing technology that works without DNA double-strand break formation. Despite rapid technological advances, in vivo application for the treatment of genetic diseases remains challenging. Here, we developed a size-reduced Sp Cas9 prime editor (PE) lacking the RNaseH domain (PE2 Δ RnH ) and an intein-split construct (PE2 p.1153) for adeno-associated virus–mediated delivery into the liver. Editing efficiencies reached 15% at the Dnmt1 locus and were further elevated to 58% by delivering unsplit PE2 Δ RnH via human adenoviral vector 5 (AdV). To provide proof of concept for correcting a genetic liver disease, we used the AdV approach for repairing the disease-causing Pah enu2 mutation in a mouse model of phenylketonuria (PKU) via prime editing. Average correction efficiencies of 11.1% (up to 17.4%) in neonates led to therapeutic reduction of blood phenylalanine, without inducing detectable off-target mutations or prolonged liver inflammation. Although the current in vivo prime editing approach for PKU has limitations for clinical application due to the requirement of high vector doses (7 × 10 14 vg/kg) and the induction of immune responses to the vector and the PE, further development of the technology may lead to curative therapies for PKU and other genetic liver diseases.

21 September 2023 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
LSLukas Schmidheini
Lukas Schmidheini
NMNicolas Mathis
Nicolas Mathis
KMKim Fabiano Marquart
Kim Fabiano Marquart
TRTanja Rothgangl
Tanja Rothgangl
LKLucas Kissling
Lucas Kissling
GSGerald Schwank
Gerald Schwank

20 May 2025 in Nature Biomedical Engineering
Verified
Journal Article
Open access
PDF file
TRTanja Rothgangl
Tanja Rothgangl
ATAndrás Tálas
András Tálas
EIEleonora I. Ioannidi
Eleonora I. Ioannidi
YWYanik Weber
Yanik Weber
DBDesirée Böck
Desirée Böck
GSGerald Schwank
Gerald Schwank
Prime editing is a versatile genome editing technology that circumvents the need for DNA double-strand break formation and homology-directed repair, making it particularly suitable for in vivo correction of pathogenic mutations. Here we developed liver-specific prime editing approaches with temporally restricted prime editor (PE) expression. We first established a dual-delivery approach where the prime editor guide RNA is continuously expressed from adeno-associated viral vectors and only the PE is transiently delivered as nucleoside-modified mRNA encapsulated in lipid nanoparticles (LNP). This strategy achieved 26.2% editing with PEmax and 47.4% editing with PE7 at the Dnmt1 locus using a single 2 mg kg−1 dose of mRNA–LNP. When targeting the pathogenic Pah enu2 mutation in a phenylketonuria mouse model, gene correction rates reached 4.3% with PEmax and 20.7% with PE7 after three doses of 2 mg kg−1 mRNA–LNP, effectively reducing blood l-phenylalanine levels from over 1,500 µmol l−1 to below the therapeutic threshold of 360 µmol l−1. Encouraged by the high efficiency of PE7, we next explored a simplified approach where PE7 mRNA was co-delivered with synthetic prime editor guide RNAs encapsulated in LNP. This strategy yielded 35.9% editing after two doses of RNA–LNP at the Dnmt1 locus and 8.0% editing after three doses of RNA–LNP at the Pah enu2 locus, again reducing l-phenylalanine levels below 360 µmol l−1. These findings highlight the therapeutic potential of mRNA–LNP-based prime editing for treating phenylketonuria and other genetic liver diseases, offering a scalable and efficient platform for future clinical translation.

7 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
YWYanik Weber
Yanik Weber
DBDesirée Böck
Desirée Böck
AIAnastasia Ivașcu
Anastasia Ivașcu
NMNicolas Mathis
Nicolas Mathis
TRTanja Rothgangl
Tanja Rothgangl
GSGerald Schwank
Gerald Schwank
Prime editing is a highly versatile genome editing technology that enables the introduction of base substitutions, insertions, and deletions. However, compared to traditional Cas9 nucleases prime editors (PEs) are less active. In this study we use OrthoRep, a yeast-based platform for directed protein evolution, to enhance the editing efficiency of PEs. After several rounds of evolution with increased selection pressure, we identify multiple mutations that have a positive effect on PE activity in yeast cells and in biochemical assays. Combining the two most effective mutations – the A259D amino acid substitution in nCas9 and the K445T substitution in M-MLV RT – results in the variant PE_Y18. Delivery of PE_Y18, encoded on DNA, mRNA or as a ribonucleoprotein complex into mammalian cell lines increases editing rates up to 3.5-fold compared to PEmax. In addition, PE_Y18 supports higher prime editing rates when delivered in vivo into the liver or brain. Our study demonstrates proof-of-concept for the application of OrthoRep to optimize genome editing tools in eukaryotic cells.

19 May 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
DBDesirée Böck
Desirée Böck
LTLisa Tidecks
Lisa Tidecks
MWMaria Wilhelm
Maria Wilhelm
YWYanik Weber
Yanik Weber
EIEleonora Ioannidi
Eleonora Ioannidi
GSGerald Schwank
Gerald Schwank
Summary: Prime editing is a highly versatile genome editing technology that holds great potential for treating genetic diseases 1, 2 . While in vivo prime editing has recently been conducted in the brain, liver, heart, and retina 3–6 , application of this technology to modulate neural circuits in the brain has not been reported yet. Here, we employ adeno-associated viral vectors to deliver optimized intein-split prime editors into the brain of mice. Delivery into newborn pups via intracerebroventricular injection resulted in up to 44.0% editing at the Dnmt1 locus in the cortex (on average 34.8±9.8% after 6 months). In addition, we obtained up to 28.1% editing at the Adrb1 locus in the cortex (on average 14.7±11.6% after 6 months). The introduced Adrb1 A187V mutation is a naturally occurring variant of the β1-adrenergic receptor, which has previously been linked to increased activity and natural short sleep 7 . Similarly, we observed an increase in the activity and exploratory behavior of treated animals. This study demonstrates the potential of prime editing for treating genetic diseases in the central nervous system and for reprogramming molecular pathways that modulate animal behavior.